 | • レポートコード：MRC2302B044 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、234ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に6,705.34百万ドルであった世界のインフルエンザワクチン市場規模が、2022年に7,285.36百万ドルになり、2027年には11,141.69百万ドルまで、年平均8.83%で成長すると予測しています。本レポートでは、インフルエンザワクチンの世界市場について調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、ワクチン種類別（不活化ワクチン、弱毒生ワクチン、組み換えワクチン）分析、年齢グループ別（青少年、成人、幼児）分析、投与経路別（筋肉内、鼻腔内、経口）分析、流通チャネル別（政府医療機関、病院＆クリニック、小売薬局、緊急治療室）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況など、以下の構成でお届けします。なお、本書には、Abbott Laboratories、AstraZeneca PLC、Bayer AG、BioDiem、BiondVax Pharmaceuticals Ltd.、Bristol-Myers Squibb Company、CanSino Biologics Inc.、Daiichi Sankyo Company, Limited、Emergent BioSolutions Inc.、Eurocept Group、Fluart Innovative Vaccines Kft.、Gamma Vaccines Pty Ltd、GlaxoSmithKline PLC、Johnson & Johnson、Merck & Co., Inc.、Pfizer Inc.、Sanofi S.A.、Seqirus GmbH、Serum Institute of India Pvt. Ltd.、Sinovac Biotech Ltd.、Swedish Orphan Biovitrum ABなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のインフルエンザワクチン市場規模：ワクチン種類別 - 不活化ワクチンの市場規模 - 弱毒生ワクチンの市場規模 - 組み換えワクチンの市場規模 ・世界のインフルエンザワクチン市場規模：年齢グループ別 - 青少年における市場規模 - 成人における市場規模 - 幼児における市場規模 ・世界のインフルエンザワクチン市場規模：投与経路別 - 筋肉内投与インフルエンザワクチンの市場規模 - 鼻腔内投与インフルエンザワクチンの市場規模 - 経口投与インフルエンザワクチンの市場規模 ・世界のインフルエンザワクチン市場規模：流通チャネル別 - 政府医療機関チャネルの市場規模 - 病院＆クリニックチャネルの市場規模 - 小売薬局チャネルの市場規模 - 緊急治療室チャネルの市場規模 ・世界のインフルエンザワクチン市場規模：地域別 - 南北アメリカのインフルエンザワクチン市場規模 アメリカのインフルエンザワクチン市場規模 カナダのインフルエンザワクチン市場規模 ブラジルのインフルエンザワクチン市場規模 ... - アジア太平洋のインフルエンザワクチン市場規模 日本のインフルエンザワクチン市場規模 中国のインフルエンザワクチン市場規模 インドのインフルエンザワクチン市場規模 韓国のインフルエンザワクチン市場規模 台湾のインフルエンザワクチン市場規模 ... - ヨーロッパ/中東/アフリカのインフルエンザワクチン市場規模 イギリスのインフルエンザワクチン市場規模 ドイツのインフルエンザワクチン市場規模 インドのインフルエンザワクチン市場規模 フランスのインフルエンザワクチン市場規模 ロシアのインフルエンザワクチン市場規模 ... - その他地域のインフルエンザワクチン市場規模 ・競争状況 ・企業情報 |
The Global Influenza Vaccine Market size was estimated at USD 6,705.34 million in 2021 and expected to reach USD 7,285.36 million in 2022, and is projected to grow at a CAGR 8.83% to reach USD 11,141.69 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Influenza Vaccine to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Vaccine Type, the market was studied across Inactivated, Live Attenuated, and Recombinant.
Based on Age Group, the market was studied across Adolescent Vaccination, Adult Vaccination, and Infant Vaccination.
Based on Administration Route, the market was studied across Intramuscular, Intranasal, and Oral.
Based on Distribution Channel, the market was studied across Government Medical Office, Hospital & Clinic, Retail Pharmacy, and Urgent Care Unit.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Influenza Vaccine market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Influenza Vaccine Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Influenza Vaccine Market, including Abbott Laboratories, AstraZeneca PLC, Bayer AG, BioDiem, BiondVax Pharmaceuticals Ltd., Bristol-Myers Squibb Company, CanSino Biologics Inc., Daiichi Sankyo Company, Limited, Emergent BioSolutions Inc., Eurocept Group, Fluart Innovative Vaccines Kft., Gamma Vaccines Pty Ltd, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Seqirus GmbH, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., and Swedish Orphan Biovitrum AB.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Influenza Vaccine Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Influenza Vaccine Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Influenza Vaccine Market?
4. What is the competitive strategic window for opportunities in the Global Influenza Vaccine Market?
5. What are the technology trends and regulatory frameworks in the Global Influenza Vaccine Market?
6. What is the market share of the leading vendors in the Global Influenza Vaccine Market?
7. What modes and strategic moves are considered suitable for entering the Global Influenza Vaccine Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Prevalence of Respiratory Disorders
5.1.1.2. Immunization as a Major Public Health Measures for the Prevention of Influenza Virus Infection
5.1.1.3. Clinical Trials and Vaccine Developments in Pipeline for Seasonal Influenzas
5.1.1.4. Government Initiatives Supporting Respiratory Health
5.1.2. Restraints
5.1.2.1. Lack of Inadequate Delivery Infrastructure & Limited Awareness
5.1.3. Opportunities
5.1.3.1. Increasing R&D Expenditure by Leading Market Players
5.1.3.2. Increasing Vaccine Availability through Distribution and Development Collaborations
5.1.3.3. Several Vaccine Candidates under Development against Animal Influenza A Virus
5.1.4. Challenges
5.1.4.1. Customers Trust and Confidence in Respiratory Disease Vaccination
5.1.4.2. Vaccine Research and Development are getting Challenged by the Constant Variations in Strains
5.2. Cumulative Impact of COVID-19
6. Influenza Vaccine Market, by Vaccine Type
6.1. Introduction
6.2. Inactivated
6.3. Live Attenuated
6.4. Recombinant
7. Influenza Vaccine Market, by Age Group
7.1. Introduction
7.2. Adolescent Vaccination
7.3. Adult Vaccination
7.4. Infant Vaccination
8. Influenza Vaccine Market, by Administration Route
8.1. Introduction
8.2. Intramuscular
8.3. Intranasal
8.4. Oral
9. Influenza Vaccine Market, by Distribution Channel
9.1. Introduction
9.2. Government Medical Office
9.3. Hospital & Clinic
9.4. Retail Pharmacy
9.5. Urgent Care Unit
10. Americas Influenza Vaccine Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Influenza Vaccine Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Influenza Vaccine Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Abbott Laboratories
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. AstraZeneca PLC
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Bayer AG
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. BioDiem
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. BiondVax Pharmaceuticals Ltd.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Bristol-Myers Squibb Company
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. CanSino Biologics Inc.
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Daiichi Sankyo Company, Limited
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Emergent BioSolutions Inc.
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Eurocept Group
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Fluart Innovative Vaccines Kft.
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Gamma Vaccines Pty Ltd
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. GlaxoSmithKline PLC
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Johnson & Johnson
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Merck & Co., Inc.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Pfizer Inc.
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Sanofi S.A.
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Seqirus GmbH
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Serum Institute of India Pvt. Ltd.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Sinovac Biotech Ltd.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Swedish Orphan Biovitrum AB
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing